126
Views
2
CrossRef citations to date
0
Altmetric
Original Article

Influence of body mass index on the prevalence and progression of dysplasia in Barrett’s esophagus: a retrospective analysis*

, , , , &
Pages 1288-1293 | Received 13 May 2016, Accepted 22 Jun 2016, Published online: 27 Jul 2016

References

  • Shaheen NJ, Falk GW, Iyer PG, et al. Clinical guideline: diagnosis and management of Barrett’s esophagus. Am J Gastroenterol. 2015;111:30–50.
  • Schlemper RJ, Riddell RH, Kato Y, et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut. 2000;47:251–255.
  • Di Pietro M, Alzoubaidi D, Fitzgerald RC. Barrett’s esophagus and cancer risk: how research advances can impact clinical practice. Gut Liver. 2014;8:356–370.
  • Corley DA, Kubo A, Levin TR, et al. Race, ethnicity, sex and temporal differences in Barrett's oesophagus diagnosis: a large community-based study, 1994–2006. Gut. 2009;58:182–188.
  • Masclee GM, Coloma PM, de Wilde M, et al. The incidence of Barrett's oesophagus and oesophageal adenocarcinoma in the United Kingdom and The Netherlands is levelling off. Aliment Pharmacol Ther. 2014;39:1321–1330.
  • Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005;97:142–146.
  • Ogden CL, Carroll MD, Kit BK, et al. Prevalence of childhood and adult obesity in the United States, 2011–2012. JAMA. 2014;311:806–814.
  • Ogden CL, Carroll MD, Fryar CD, et al. Prevalence of obesity among adults and youth: United States, 2011–2014. NCHS Data Brief. 2015;1–8.
  • Rubenstein JH. Risk factors for Barrett's esophagus. Curr Opin Gastroenterol. 2014;30:408–414.
  • Naef AP, Savary M, Ozzello L. Columnar-lined lower esophagus: an acquired lesion with malignant predisposition. Report on 140 cases of Barrett's esophagus with 12 adenocarcinomas. J Thorac Cardiovasc Surg. 1975;70:826–835.
  • Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med. 2005;143:199–211.
  • Corley DA, Kubo A. Body mass index and gastroesophageal reflux disease: a systematic review and meta-analysis. Am J Gastroenterol. 2006;101:2619–2628.
  • Crowell MD, Bradley A, Hansel S, et al. Obesity is associated with increased 48-h esophageal acid exposure in patients with symptomatic gastroesophageal reflux. Am J Gastroenterol. 2009;104:553–559.
  • Nadaleto BF, Herbella FAM, Patti MG. Gastroesophageal reflux disease in the obese: pathophysiology and treatment. Surgery. 2016;159:475–486.
  • Bu X, Ma Y, Der R, et al. Body mass index is associated with Barrett esophagus and cardiac mucosal metaplasia. Dig Dis Sci. 2006;51:1589–1594.
  • Stein DJ, El-Serag HB, Kuczynski J, et al. The association of body mass index with Barrett's oesophagus. Aliment Pharmacol Ther. 2005;22:1005–1010.
  • Cook MB, Greenwood DC, Hardie LJ, et al. A systematic review and meta-analysis of the risk of increasing adiposity on Barrett's esophagus. Am J Gastroenterol. 2008;103:292–300.
  • Chen Q, Zhuang H, Liu Y. The association between obesity factor and esophageal cancer. J Gastrointest Oncol. 2012;3:226–231.
  • Kubo A, Corley DA. Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2006;15:872–878.
  • Rustgi AK, El-Serag HB. Esophageal carcinoma. N Engl J Med. 2014;371:2499–2509.
  • Haggitt RC. Barrett's esophagus, dysplasia, and adenocarcinoma. Hum Pathol. 1994;25:982–993.
  • Fléjou J-F. Barrett’s oesophagus: from metaplasia to dysplasia and cancer. Gut. 2005;54:i6–i12.
  • Anderson LA, Watson RGP, Murphy SJ, et al. Risk factors for Barrett's oesophagus and oesophageal adenocarcinoma: results from the FINBAR study. World J Gastroenterol. 2007;13:1585–1594.
  • de Jonge PJF, Steyerberg EW, Kuipers EJ, et al. Risk factors for the development of esophageal adenocarcinoma in Barrett's esophagus. Am J Gastroenterol. 2006;101:1421–1429.
  • Oberg S, Wenner J, Johansson J, et al. Barrett esophagus: risk factors for progression to dysplasia and adenocarcinoma. Ann Surg. 2005;242:49–54.
  • Vaughan TL, Kristal AR, Blount PL, et al. Nonsteroidal anti-inflammatory drug use, body mass index, and anthropometry in relation to genetic and flow cytometric abnormalities in Barrett’s esophagus. Cancer Epidemiol Biomarkers Prev. 2002;11:745–752.
  • Kristal AR, Blount PL, Schenk JM, et al. Low-fat, high fruit and vegetable diets and weight loss do not affect biomarkers of cellular proliferation in Barrett esophagus. Cancer Epidemiol Biomarkers Prev. 2005;14:2377–2383.
  • Chandar AK, Iyer PG. Role of obesity in the pathogenesis and progression of Barrett's esophagus. Gastroenterol Clin N Am. 2015;44:249–264.
  • Murray L, Romero Y. Role of obesity in Barrett's esophagus and cancer. Surg Oncol Clin N Am. 2009;18:439–452.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.